Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Naeem, A; Utro, F; Wang, Q; Cha, JS; Vihinen, M; Martindale, S; Zhou, YL; Ren, Y; Tyekucheva, S; Kim, AS; Fernandes, SM; Saksena, G; Rhrissorrakrai, K; Levovitz, C; Danysh, BP; Slowik, K; Jacobs, RA; Davids, MS; Lederer, JA; Zain, R; Smith, CIE; Leshchiner, I; Parida, L; Getz, G; Brown, JR

Brown, JR (通讯作者)，Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.;Brown, JR (通讯作者)，Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.

BLOOD ADVANCES, 2023; 7 (9): 1929

Abstract

Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has bee......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索